Search results for "Antibodies"

showing 10 items of 1885 documents

Interrelation of peptidergic innervation with mast cells and ED1-positive cells in rat thymus

1991

The peptidergic innervation of rat thymus has been investigated by immunohistochemical methods, focusing on the spatial interrelationship of peptidergic nerve fibers with mast cells and macrophages in the rat. An antiserum directed against the protein gene product 9.5 (PGP 9.5) regarded as a pan-neuronal marker revealed a rich innervation, especially in the subcapsular cortex, in interlobular septa, and of the vasculature in the cortex and the corticomedullary boundary. A minor proportion of PGP 9.5-immunoreactive (ir) fibers supplied the thymic parenchyma. The main component of peptidergic innervation consisted of fibers costaining for tachykinins (TKs) and calcitonin gene-related peptide …

medicine.medical_specialtyPathologyNeuroimmunomodulationImmunologyVasoactive intestinal peptideConnective tissueNerve fiberThymus GlandBiologyCalcitonin gene-related peptideBehavioral NeuroscienceCatecholaminesNerve FibersInternal medicineCortex (anatomy)medicineAnimalsMast CellsGalaninEndocrine and Autonomic SystemsMacrophagesNeuropeptidesAntibodies MonoclonalCell DifferentiationRats Inbred StrainsMast cellRatsReceptors NeurotransmitterEndocrinologymedicine.anatomical_structurePeripheral nervous systemUbiquitin ThiolesteraseBiomarkersBrain, Behavior, and Immunity
researchProduct

Inhibitors to factor VII in congenital factor VII deficiency.

2014

medicine.medical_specialtyPediatricsFactor VIIbusiness.industryInhibitorsFactor VII DeficiencyMEDLINErVIIaHematologyGeneral MedicineFactor VIIInhibitors Factor VII deficiencyGastroenterologyAntibodieschemistry.chemical_compoundchemistryInternal medicinerVIIa; FVII deficiency; InhibitorsmedicineHumansFVII deficiencyFactor VII deficiencybusinessGenetics (clinical)
researchProduct

Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society

2011

Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficacious in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.

medicine.medical_specialtyPediatricspml; iris; multiple sclerosis; natalizumabMultiple SclerosisNeurologypmlMEDLINEProgressive MultifocalDermatologyRelapsing-RemittingAntibodies Monoclonal HumanizedAntibodiesLeukoencephalopathyMultiple Sclerosis Relapsing-RemittingNatalizumabLeukoencephalopathyMonoclonalmedicineHumansAdverse effectAntibodies; Monoclonal; Humanized Antibodies; therapeutic use Humans Leukoencephalopathy; Progressive Multifocal; chemically induced Multiple Sclerosis; Relapsing-Remitting; drug therapyHumanizedMultiple sclerosis Natalizumab PML IRISirisbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisLeukoencephalopathy Progressive MultifocalAntibodies MonoclonalGeneral Medicinemedicine.diseasedrug therapyPsychiatry and Mental healththerapeutic usechemically inducednatalizumab multiple sclerosis treatment guidelinesPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)Neurosurgerybusinessmedicine.drug
researchProduct

Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis

2020

AbstractObjectiveThe randomized, controlled MAINRITSAN2 trial was designed to compare the capacity of an individually tailored therapy [randomization day 0 (D0)], with reinfusion only when CD19+ lymphocytes or ANCA had reappeared, or if the latter’s titre rose markedly, with that of five fixed-schedule 500-mg rituximab infusions [D0 + D14, then months (M) 6, 12 and 18] to maintain ANCA-associated vasculitis (AAV) remissions. Relapse rates did not differ at M28. This ancillary study was undertaken to evaluate the effect of omitting the D14 rituximab infusion on AAV relapse rates at M12.MethodsMAINRITSAN2 trial data were subjected to post-hoc analyses of M3, M6, M9 and M12 relapse-free surviv…

medicine.medical_specialtyRandomizationAntigens CD19Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGastroenterologyDisease-Free SurvivalDrug Administration ScheduleAntibodies Antineutrophil CytoplasmicMaintenance Chemotherapylaw.invention03 medical and health sciences0302 clinical medicineRheumatologyMaintenance therapyRandomized controlled triallawInternal medicinePost-hoc analysismedicineHumansPharmacology (medical)030212 general & internal medicineSurvival rate030203 arthritis & rheumatologybusiness.industrymedicine.diseaseAntirheumatic AgentsRituximabRituximabMicroscopic polyangiitisGranulomatosis with polyangiitisbusinessmedicine.drugRheumatology
researchProduct

Search for autoantibodies to the human bradykinin B2 receptor.

1997

medicine.medical_specialtyReceptor Bradykinin B2Blotting WesternMolecular Sequence DataEnzyme-Linked Immunosorbent AssayAntigen-Antibody ComplexCross ReactionsChromatography AffinityCohort StudiesHypertension MalignantAdjuvants ImmunologicInternal medicineMedicineAnimalsHumansAmino Acid SequenceBradykinin receptorAntigensAutoantibodiesPharmacologyBinding Sitesbusiness.industryReceptors BradykininAutoantibodyPrecipitin TestsRecombinant ProteinsEndocrinologyImmunoglobulin GHemocyaninsFemaleRabbitsbusinessPeptidesBradykinin B2 ReceptorBaculoviridaeImmunopharmacology
researchProduct

The new criteria for classification of rheumatoid arthritis: what we need to know for clinical practice.

2011

The new criteria for classification of Rheumatoid Arthritis have been recently released. They incorporate the anti-Citrullinated Protein antibody testing and the other classic criteria in a score system (the diagnosis of definite rheumatoid arthritis is made by a total score ≥6). These criteria try to meet the pressing needs to gain sensitivity in early disease. Symptoms, elevated acute-phase response, serologic abnormality, joint involvement were all considered for scoring after confirming the presence of synovitis in at least 1 joint in the absence of an alternative diagnosis that better explains the synovitis. However, no sensitivity and specificity has been showed. Moreover, Area Under …

medicine.medical_specialtySettore MED/09 - Medicina InternaArthritisDiseasePeptides CyclicSensitivity and SpecificityArthritis RheumatoidRheumatologyInternal medicineSynovitisInternal MedicineMedicineHumansIntensive care medicineAutoantibodiesReceiver operating characteristicbusiness.industryAutoantibodymedicine.diseaseSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheRheumatoid arthritis Classification criteria Anti-citrullinated peptide autoantibodies Bayesian reasoning Likelihood ratio Sensitivity and specificityRheumatologySettore MED/16 - ReumatologiaRheumatoid arthritisPhysical therapyAbnormalitybusinessBiomarkersEuropean journal of internal medicine
researchProduct

The production of the oral mucosa of antiendomysial and anti-tissue-transglutaminase antibodies in patients with celiac disease: a review.

2010

Celiac disease (CD) is a lifelong, T cell—mediated enteropathy, triggered by the ingestion of gluten and related prolamins in genetically susceptible subjects, resulting in minor intestinal mucosal injury, including villous atrophy with crypt hyperplasia and intraepithelial lymphocytosis, and subsequent nutrient malabsorption. Although serological tests for antiendomysial (EMA) and anti—tissue transglutaminase (anti-tTG) autoantibodies are used to screen and follow up on patients with CD, diagnostic confirmation is still based on the histological examination of the small intestinal mucosa. Although the small intestinal mucosa is the main site of the gut involved in CD, other mucosal surface…

medicine.medical_specialtySettore MED/09 - Medicina InternaMalabsorptionGlutensTissue transglutaminaseBiopsyantiendomysial antibodieslcsh:Medicineoral biopsyReview Articlelcsh:TechnologyGastroenterologySensitivity and SpecificityGeneral Biochemistry Genetics and Molecular BiologySettore MED/28 - Malattie Odontostomatologicheanti–tissue transglutaminase antibodiesInternal medicineBiopsymedicineHumansEnteropathyOral mucosalcsh:ScienceGeneral Environmental ScienceAutoantibodiesSettore MED/12 - GastroenterologiaGastrointestinal tractTransglutaminasesbiologymedicine.diagnostic_testoral mucosalcsh:Tbusiness.industrylcsh:RMouth MucosaMuscle SmoothGeneral Medicinemedicine.diseaseCeliac Diseasemedicine.anatomical_structureceliac disease oral mucosa anti–tissue transglutaminase antibodies antiendomysial antibodies oral biopsy.Immunologybiology.proteinIntraepithelial lymphocytelcsh:QGliadinbusinessTheScientificWorldJournal
researchProduct

Responses to self and non-self intestinal microflora in health and inflammatory bowel disease.

1997

medicine.medical_specialtyT-LymphocytesImmunologyBiologyCross ReactionsInflammatory bowel diseaseGastroenterologyAntibodiesImmune tolerancePathogenesisMiceImmune systemCrohn DiseaseInternal medicinemedicineAnimalsHumansCrohn diseaseCross reactionsmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisInterleukin-12Interleukin-10IntestinesInterleukin 10Disease Models AnimalImmunologyForecastingResearch in immunology
researchProduct

Expression of differentiation antigens and growth-related genes in normal kidney, autosomal dominant polycystic kidney disease, and renal cell carcin…

1992

Cellular differentiation and mRNA levels of genes involved in kidney growth were investigated in normal kidney cells, cyst-lining epithelial cells of polycystic kidney disease, and renal carcinoma cells (RCC). All cells comparatively studied exhibited an antigenic phenotype of proximal tubular cells as shown by the expression of a panel of brush border membrane enzymes and kidney-associated cell surface antigens. The epithelial developmental antigen Exo-1 was expressed in 50% to 80% of cyst-lining epithelia in polycystic kidney tissue and in 20% to 30% of polycystic kidney cells cultured in vitro. Normal kidney cells and RCC were negative under identical culture conditions. The expression o…

medicine.medical_specialtyTGF alphaCellular differentiationAutosomal dominant polycystic kidney diseaseGene ExpressionBiologyKidneyEpitheliumProto-Oncogene Proteins c-mycGrowth factor receptorEpidermal growth factorInternal medicinemedicinePolycystic kidney diseaseHumansRNA MessengerGrowth SubstancesCarcinoma Renal CellCells CulturedKidneyurogenital systemAntibodies MonoclonalTransforming Growth Factor alphamedicine.diseasePolycystic Kidney Autosomal DominantAntigens DifferentiationImmunohistochemistryKidney NeoplasmsErbB ReceptorsEndocrinologymedicine.anatomical_structureGenesNephrologyAntigens SurfaceCancer researchTransforming growth factorAmerican journal of kidney diseases : the official journal of the National Kidney Foundation
researchProduct

Haemolytic-uraemic syndrome during severe lupus nephritis: efficacy of plasma exchange

2012

Systemic lupus erythematosus (SLE) has been described as a cause of thrombotic microangiopathy, especially thrombotic thrombocytopenic purpura (TTP). Haemolytic-uraemic syndrome (HUS) is less frequent in SLE. We report a case of such an association during an episode of severe lupus nephritis in a young woman, who was successfully treated with steroids, cyclophosphamide and especially plasma exchange with plasma replacement. This report highlights the importance of recognising atypical HUS in SLE patients by looking for schistocytes in case of haemolytic anemia with a negative antiglobulin test, in order to begin plasma exchange.

medicine.medical_specialtyThrombotic microangiopathyCyclophosphamidebusiness.industryAnemiaThrombotic thrombocytopenic purpuraLupus nephritismedicine.diseaseGastroenterologySchistocytePharmacotherapyimmune system diseaseshemic and lymphatic diseasesInternal medicineInternal MedicineMedicineskin and connective tissue diseasesbusinessAnti-SSA/Ro autoantibodiesmedicine.drugInternal Medicine Journal
researchProduct